At a glance
ClinicalIndex Comparison RecordPhase 1Active· 72 target
Drug / intervention
Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase I Study of Hu8F4 in Patients With Advanced Hematologic Malignancies
In Brief
A Phase 1 clinical trial evaluating Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4, Laboratory Biomarker Analysis, and 1 other intervention for Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome and 10 related conditions. Active but no longer recruiting, targeting 72 participants across 4 sites.
Detailed Summary
This phase I trial studies the side effects and best dose of anti-PR1/HLA-A2 monoclonal antibody Hu8F4 (Hu8F4) in treating patients with malignancies related to the blood (hematologic). Monoclonal antibodies, such as Hu8F4, may interfere with the ability of cancer cells to grow and spread.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid Cell Neoplasm, High Risk Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts-1, Myelodysplastic Syndrome With Excess Blasts-2, Myelofibrosis, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Refractory Chronic Myelomonocytic Leukemia, Secondary Acute Myeloid Leukemia
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 1Active
201620172018201920202021202220232024202520262027
First PostedAug 2015
Enrollment StartJan 2019
TodayJul 2026
Primary CompletionJan 2027
First PostedAug 20, 2015
Enrollment StartJan 31, 2019
Primary CompletionJan 1, 2027
TodayJul 1, 2026
Enrollment to primary: 7.9 yearsPosted 10.9 years agoPrimary completion in 6 months
Interventions
Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4drug
Given IV
Laboratory Biomarker Analysisother
Correlative studies
Pharmacological Studyother
Correlative studies